Thursday, February 11, 2016 5:50:02 PM
CytoSorb - Polymer-based system for adsorbing cytokines
Column CytoSorb
Attention! The system is a consumable item for single use only!
CytoSorb system - nonpyrogenic sterile biocompatible system for a single application designed for the removal of cytokines from the patient's blood by adsorption of using polymeric adsorbent peas contained within the system. A container with an adsorbent CytoSorb secured in a holder on the bar or IV pole, then use CytoSorb adapters connected to the extracorporeal circuit (mains) Blood Pump. The system works with any commercially available blood pump capable of providing flow rates up to 400 mL / min: it can be heart-lung machine, the machine of extracorporeal membrane oxygenation, apparatus for continuous renal replacement therapy, hemodialysis machine. Indications for use CytoSorb system: CytoSorb shows for use in cases of "cytokine storm", ie uncontrolled and not carrying the protective function of the activation of immune cells by cytokines in inflammation and the release of the latest new portion of cytokines due to the direct link between these processes. This occurs in the following cases: sepsis of any etiology; acute respiratory distress syndrome; during operations in cardiovascular and thoracic surgery; in septic patients with gipervospaleniem; in patients after surgery with severe sepsis and acute kidney damage beginning; in patients with acute concomitant diseases and sepsis (a weakened immune system), patients on chronic dialysis; in patients with chronic liver disease. The principle of operation CytoSorb system: Whole blood of the patient, anticoagulated with heparin or citrate throughput CytoSorb, mounted in a holder and connected via adapters in the standard line the blood pump (pump must be able to provide blood flow to 400 ml / min and have a pressure sensor in the lines). Inside CytoSorb occurs hydrophobic interactions (the molecules are drawn into the pores of the material selectively substances with a high concentration of adsorbed more strongly than the substance with a low concentration) spanning proteins average molecular weight, such as cytokines, peas adsorbent into the pores, depending on their concentration in the blood. Adsorbed CytoSorb cytokines remain in the system. More blood on highways perfusion pump returned to the patient. The pore size of the adsorbent within the peas systems allow particles to adsorb a molecular weight of about 8 to 55 kDa. Thus albumin and other proteins of high molecular weight remain in the patient's blood while other sorbents absorb and albumin. The adsorption particles CytoSorb system: The following is a graph illustrating various kinds of cytokines, which are subjected to adsorption using CytoSorb system indicating their sizes . Blue parabola CytoSorb designates the action system. Comments to the scheme: the white color on the chart denote proinflammatory cytokines yellow -protivovospalitelnye cytokines (IL-1ra, IL-13, IL-10, IL-4, TGF- ß), and soluble receptor sTNFR tumor necrosis factor, which is anti-inflammatory mediator. The height of the vertical columns scheme bears no semantic load. Other molecules whose concentration is reduced by CytoSorb: - myoglobin (molecular weight of 17 kDa) . - Bilirubin (MW 8 kD) CytoSorb on blood electrolyte balance is not affected. (D. Shedler et al. Journal of Critical Care 2013, 17 (Supplement 2): P.62 / D Schädler, et al; Critical Care 2013, 17 (Suppl 2):. P62) albumin minialny losses and account for less than 5% (D. Shedler etc. Magazine. critical Care 2013, 17 (Supplement 2): P.62 / D Schädler, et al; critical Care 2013, 17 (Suppl 2):. P62) The levels of C3a and C5b-9 (important quickly produced after the activation of the complement system proteins) in plasma are not rising, that is the use of CytoSorb does not trigger an immune cascade. An additional, apart from the standard, the level of monitoring of the concentration of cytokines during the use of the System is not required.
http://www.intensivmed.ru/index.php?option=com_content&view=category&layout=blog&id=42&Itemid=130&lang=ru
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:35:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:00 PM
- CytoSorbents Reports First Quarter 2024 Results • GlobeNewswire Inc. • 05/09/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM